Kaseje Neema, Lüthold Samuel, Mentha Gilles, Toso Christian, Belli Dominique, McLin Valérie, Wildhaber Barbara
Department of Pediatric Surgery, University Children's Hospital Geneva, 6 rue Willy Donzé, Geneva, Switzerland.
Eur J Pediatr Surg. 2013 Feb;23(1):8-13. doi: 10.1055/s-0032-1329703. Epub 2012 Nov 19.
With the rising demand for liver transplantations (LTs), and the shortage of organs, extended criteria including donor hypernatremia have been adopted to increase the donor pool. Currently, there is conflicting evidence on the effect of donor hypernatremia on outcomes following LT. Our aim was to investigate differences in outcome in patients receiving grafts from hypernatremic donors compared with patients receiving grafts from normonatremic donors in the pediatric population.
We retrospectively reviewed 94 pediatric patients with LTs from 1994 to 2011. We divided the patients into two groups: patients receiving organs from donors with sodium levels < 150 µmol/L, n = 67 (group 1), and patients receiving organs from donors with sodium levels ≥ 150 µmol/L, n = 27 (group 2). Using proportions and means, we analyzed patient age, sex, weight, model for end-stage liver disease (MELD) score, primary diagnosis, emergency of procedure, intraoperative transfusion volume, cold ischemia time, donor age, graft type, and postoperative graft function. Rates of mortality, rejection, early biliary, infectious, and vascular complications were calculated.
Mean age was 3.9 years in group 1 and 3.7 years in group 2 (p = 0.69). Mean weight and MELD scores were similar in the two study groups (16.0 vs. 15.9 and 21.2 vs. 22.0, respectively). There were no significant differences in mean cold ischemia times 6.4 versus 6.9 hours (p = 0.29), and mean intraoperative transfusion volumes 1,068.5 mL versus 1,068.8 mL (p = 0.89). There were no statistically significant differences in mortality rates (7.3 vs. 11.1%, p = 0.68). Prothrombin time (PT) at day 10 post-LT was significantly lower in group 2 (79 vs. 64, p = 0.017), and there was a higher relative risk (RR) for early thrombotic vascular complications in group 2 (RR = 2.48); however, this was not significant (p = 0.26). No significant differences in RR for rejection (0.97, p = 0.86), viral infections (1.24, p = 0.31), bacterial infections (0.86, p = 0.62), or early biliary complications (1.03, p = 1.00) were observed.
In pediatric LT patients receiving grafts from hypernatremic donors, there are no significant increases in rates of mortality, rejection, early biliary, and infectious complications. However, there is a statistically significant lower PT at postoperative day 10 following transplantation, and a more than double RR for early thrombotic vascular complications although this was not statistically significant.
随着肝移植(LT)需求的不断增加以及器官短缺,包括供体高钠血症在内的扩大标准已被采用以增加供体库。目前,关于供体高钠血症对肝移植后结局的影响存在相互矛盾的证据。我们的目的是调查在儿科人群中,接受高钠血症供体肝脏移植的患者与接受正常钠血症供体肝脏移植的患者在结局上的差异。
我们回顾性分析了1994年至2011年期间94例接受肝移植的儿科患者。我们将患者分为两组:接受钠水平<150 μmol/L供体器官的患者,n = 67(第1组),以及接受钠水平≥150 μmol/L供体器官的患者,n = 27(第2组)。我们使用比例和均值分析了患者的年龄、性别、体重、终末期肝病模型(MELD)评分、主要诊断、手术急诊情况、术中输血量、冷缺血时间、供体年龄、移植物类型和术后移植物功能。计算了死亡率、排斥反应率、早期胆道、感染和血管并发症的发生率。
第1组的平均年龄为3.9岁,第2组为3.7岁(p = 0.69)。两个研究组的平均体重和MELD评分相似(分别为16.0对15.9和21.2对22.0)。平均冷缺血时间(6.4对6.9小时,p = 0.29)和平均术中输血量(1068.5 mL对1068.8 mL,p = 0.89)无显著差异。死亡率无统计学显著差异(7.3%对11.1%,p = 0.68)。肝移植术后第10天,第2组的凝血酶原时间(PT)显著更低(79对64,p = 0.017),并且第2组早期血栓形成性血管并发症的相对风险(RR)更高(RR = 2.48);然而,这并不显著(p = 0.26)。在排斥反应(RR = 0.97,p = 0.86)、病毒感染(RR = 1.24,p = 0.31)、细菌感染(RR = 0.86,p = 0.62)或早期胆道并发症(RR = 1.03,p = 1.00)的RR方面未观察到显著差异。
在接受高钠血症供体肝脏移植的儿科肝移植患者中,死亡率、排斥反应率、早期胆道和感染并发症的发生率没有显著增加。然而,移植后第10天术后PT在统计学上显著更低,并且早期血栓形成性血管并发症的RR增加了一倍多,尽管这在统计学上并不显著。